Systemic siRNA-mediated gene silencing: A new approach to targeted therapy of cancer

Annals of Surgery

Volumn 240, Issue 4, 2004, Pages 667-676

  Duxbury, Mark S ^a   Matros, Evan ^a   Ito, Hiromichi ^a   Zinner, Michael J ^a   Ashley, Stanley W ^a   Whang, Edward E ^a,b   Reber, Howard A ^b   Bell Jr , Richard H ^b   Pitt, Henry A ^b   Hammond, Graeme L ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 6; CD34 ANTIGEN; CELL ADHESION MOLECULE; KI 67 ANTIGEN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; GENE SILENCING; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTIGENS, NEOPLASM; APOPTOSIS; CELL ADHESION MOLECULES; CELL DIVISION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TARGETING; GENE THERAPY; HUMANS; KI-67 ANTIGEN; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SKIN NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 4644316534     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sla.0000140755.97224.9a     Document Type: Conference Paper

References (30)

1. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
2. Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391:806-811.
3. Hannon GJ. RNA interference. Nature. 2002;418:244-251.
4. Thompson JA, Grunert F, Zimmermann W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal. 1991;5:344-366.
5. Kuroki M, Abe H, Imakiirei T, et al. Identification and comparison of residues critical for cell-adhesion activities of two neutrophil CD66 antigens, CEACAM6 and CEACAM8. J Leukoc Biol. 2001;70:543-550.
6. Jantscheff P, Terracciano L, Lowy A, et al. Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance. J Clin Oncol. 2003;21:3638-3646.
7. Kodera Y, Isobe K, Yamauchi M, et al. Expression of carcinoembryonic antigen (CEA) and nonspecific crossreacting antigen (NCA) in gastrointestinal cancer; the correlation with degree of differentiation. Br J Cancer. 1993;68:130-136.
8. Hasegawa T, Isobe K, Tsuchiya Y, et al. Nonspecific crossreacting antigen (NCA) is a major member of the carcinoembryonic antigen (CEA)-related gene family expressed in lung cancer. Br J Cancer. 1993;67:58-65.
9. Ilantzis C, DeMarte L, Screaton RA, et al. Deregulated expression of the human tumor marker CEA and CEA family member CEACAM6 disrupts tissue architecture and blocks colonocyte differentiation. Neoplasia. 2002;4:151-163.
10. Scholzel S, Zimmermann W, Schwarzkopf G, et al. Carcinoembryonic antigen family members CEACAM6 and CEACAM7 are differentially expressed in normal tissues and oppositely deregulated in hyperplastic colorectal polyps and early adenomas. Am J Pathol. 2000;156:595-605.
11. Duxbury MS, Ito H, Zinner MJ, et al. CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells. Oncogene. 2004;23:465-473.
12. Raitano AB, Scuderi P, Korc M. Binding and biological effects of tumor necrosis factor and gamma interferon in human pancreatic carcinoma cells. Pancreas. 1990;5:267-277.
13. Sun FX, Tohgo A, Bouvet M, et al. Efficacy of camptothecin analog DX-8951f (Exatecan Mesylate) on human pancreatic cancer in an orthotopic metastatic model. Cancer Res. 2003;63:80-85.
14. Demicheli R, Foroni R, Ingrosso A, et al. An exponential-Gompertzian description of LoVo cell tumor growth from in vivo and in vitro data. Cancer Res. 1989;49:6543-6546.
15. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol. 1994;124:619-626.
16. Westermark B. The deficient density-dependent growth control of human malignant glioma cells and virus-transformed glia-like cells in culture. Int J Cancer. 1973;12:438-451.
17. Shanmugathasan M, Jothy S. Apoptosis, anoikis and their relevance to the pathobiology of colon cancer. Pathol Int. 2000;50:273-279.
18. Streuli CH, Gilmore AP. Adhesion-mediated signaling in the regulation of mammary epithelial cell survival. J Mammary Gland Biol Neoplasia. 1999;4:183-191.
19. Yawata A, Adachi M, Okuda H, et al. Prolonged cell survival enhances peritoneal dissemination of gastric cancer cells. Oncogene. 1998;16:2681-2686.
20. Duxbury MS, Ito H, Zinner MJ, et al. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene. 2003;311:786-792.
21. Duxbury MS, Ito H, Benoit E, et al. RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochem Biophys Res Commun. 2003;311:786-792.
22. Duxbury MS, Ito H, Zinner MJ, et al. EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene. 2004;23:1448-1456.
23. Filleur S, Courtin A, Ait-Si-Ali S, et al. SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res. 2003;63:3919-3922.
24. Song E, Lee SK, Wang J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med. 2003;9:347-351.
25. Zender L, Hutker S, Liedtke C, et al. Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc Natl Acad Sci U S A. 2003;100:7797-7802.
26. Bertrand JR, Pottier M, Vekris A, et al. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun. 2002;296:1000-1004.
27. Aoki Y, Cioca DP, Oidaira H, et al. RNA interference may be more potent than antisense RNA in human cancer cell lines. Clin Exp Pharmacol Physiol. 2003;30:96-102.
28. Dvorak HF. Leaky tumor vessels: consequences for tumor stroma generation and for solid tumor therapy. Prog Clin Biol Res. 1990;354A: 317-330.
29. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumor-igenicity by virus-mediated RNA interference. Cancer Cell. 2002;2:243-247.
30. Wilda M, Fuchs U, Wossmann W, et al. Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene. 2002;21:5716-5724.